CHLORPROMAZINE Drug Patent Profile
✉ Email this page to a colleague
When do Chlorpromazine patents expire, and when can generic versions of Chlorpromazine launch?
Chlorpromazine is a drug marketed by Actavis Mid Atlantic, Genus, Pharm Assoc, Wockhardt, Abraxis Pharm, Dr Reddys, Eugia Pharma, Marsam Pharms Llc, Watson Labs, West-ward Pharms Int, Wyeth Ayerst, Alpharma Us Pharms, Abbott, Alembic, Amneal Pharms Co, Appco, Cycle, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Kv Pharm, Lannett Co Inc, Lederle, Lupin, MSN, Purepac Pharm, Pvt Form, Sandoz, Sun Pharm, Teva Pharms, Upsher Smith Labs, Vangard, West Ward, Zameer Pharms, Zydus, and Hikma. and is included in sixty-seven NDAs.
The generic ingredient in CHLORPROMAZINE is chlorpromazine hydrochloride. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the chlorpromazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chlorpromazine
A generic version of CHLORPROMAZINE was approved as chlorpromazine hydrochloride by ZYDUS on January 17th, 2020.
Summary for CHLORPROMAZINE
US Patents: | 0 |
Applicants: | 35 |
NDAs: | 67 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CHLORPROMAZINE |
DailyMed Link: | CHLORPROMAZINE at DailyMed |
Recent Clinical Trials for CHLORPROMAZINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cancer Prevention Research Institute of Texas | Phase 2/Phase 3 |
Sadat City University | Phase 1/Phase 2 |
Varun Monga, MD | Phase 1 |